thalidomide has been researched along with Neoplasms, Plasma Cell in 7 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Neoplasms, Plasma Cell: Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with relapsed/refractory multiple myeloma (RRMM) need proven subsequent therapies after early-line lenalidomide treatment failure." | 9.51 | Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial. ( Acosta-Rivera, M; Agarwal, A; Anz, B; Bahlis, NJ; Bar, M; Berdeja, J; Chung, W; Fonseca, G; Ganguly, S; Lee, K; Matous, J; Mouro, J; Quick, D; Reece, D; Samaras, C; Schiller, GJ; Sebag, M; Seet, CS; Siegel, DS; Song, K, 2022) |
| "Patients with relapsed/refractory multiple myeloma (RRMM) need proven subsequent therapies after early-line lenalidomide treatment failure." | 5.51 | Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial. ( Acosta-Rivera, M; Agarwal, A; Anz, B; Bahlis, NJ; Bar, M; Berdeja, J; Chung, W; Fonseca, G; Ganguly, S; Lee, K; Matous, J; Mouro, J; Quick, D; Reece, D; Samaras, C; Schiller, GJ; Sebag, M; Seet, CS; Siegel, DS; Song, K, 2022) |
| "Myelodysplastic syndromes with chromosome 5 long arm deletion (5q-mds) may benefit from lenalidomide treatment." | 3.85 | Concomitant Occurrence of Blastic Plasmacytoid Dendritic Cell Neoplasm and Acute Myeloid Leukaemia after Lenalidomide Treatment for. ( Cortelezzi, A; Fattizzo, B; Ferla, V; Fracchiolla, NS; Freyrie, A; Iurlo, A; Reda, G, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 4 (57.14) | 2.80 |
| Authors | Studies |
|---|---|
| Bahlis, NJ | 1 |
| Siegel, DS | 1 |
| Schiller, GJ | 1 |
| Samaras, C | 1 |
| Sebag, M | 1 |
| Berdeja, J | 1 |
| Ganguly, S | 1 |
| Matous, J | 1 |
| Song, K | 1 |
| Seet, CS | 1 |
| Acosta-Rivera, M | 1 |
| Bar, M | 1 |
| Quick, D | 1 |
| Anz, B | 1 |
| Fonseca, G | 1 |
| Chung, W | 1 |
| Lee, K | 1 |
| Mouro, J | 1 |
| Agarwal, A | 1 |
| Reece, D | 1 |
| Martin, T | 1 |
| Richardson, PG | 1 |
| Facon, T | 1 |
| Moreau, P | 1 |
| Perrot, A | 1 |
| Spicka, I | 1 |
| Bisht, K | 1 |
| Inchauspé, M | 1 |
| Casca, F | 1 |
| Macé, S | 1 |
| Van de Velde, H | 1 |
| Suzuki, K | 1 |
| Zander, T | 1 |
| Pabst, T | 1 |
| Schär, S | 1 |
| Aebi, S | 1 |
| Mey, U | 1 |
| Novak, U | 1 |
| Lerch, E | 1 |
| Rhyner Agocs, G | 1 |
| Goede, J | 1 |
| Maniecka, Z | 1 |
| Hayoz, S | 1 |
| Rüfer, A | 1 |
| Renner, C | 1 |
| Driessen, C | 1 |
| Costa, LJ | 1 |
| Giri, S | 1 |
| Bal, S | 1 |
| Ravi, G | 1 |
| Godby, KN | 1 |
| Fracchiolla, NS | 1 |
| Iurlo, A | 1 |
| Ferla, V | 1 |
| Fattizzo, B | 1 |
| Freyrie, A | 1 |
| Reda, G | 1 |
| Cortelezzi, A | 1 |
| Scott, AP | 1 |
| Mollee, P | 1 |
| Yeung, CK | 1 |
| Loong, F | 1 |
| Kwong, YL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2, Multicenter, Multi-cohort, Open-label Study of Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following[NCT01946477] | Phase 2 | 186 participants (Actual) | Interventional | 2014-05-29 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for thalidomide and Neoplasms, Plasma Cell
| Article | Year |
|---|---|
Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenal | 2022 |
Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Re | 2023 |
5 other studies available for thalidomide and Neoplasms, Plasma Cell
| Article | Year |
|---|---|
Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Hu | 2022 |
Drug class refractoriness, not number of prior lines of therapy, properly classify patients with relapsed and refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Re | 2023 |
Concomitant Occurrence of Blastic Plasmacytoid Dendritic Cell Neoplasm and Acute Myeloid Leukaemia after Lenalidomide Treatment for.
Topics: Chromosome Deletion; Dendritic Cells; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, | 2017 |
Pomalidomide - Author Reply.
Topics: Australia; Humans; Multiple Myeloma; Neoplasms, Plasma Cell; Thalidomide | 2019 |
Scleromyxoedema due to a plasma cell neoplasm: rapid remission with bortezomib, thalidomide and dexamethasone.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Middle Aged; Neopla | 2012 |